BACK TO ALL REFERENCES
Stayble Therapeutics: Injectable treatment (STA-363) for chronic low back pain
Stayble Therapeutics AB is a Swedish life science SME which develops an injectable treatment (STA-363) for chronic low back pain (cLBP) caused by spinal disc degeneration.
€50 k
in funding
5
years
Key numbers
About the project
Stayble Therapeutics AB is a Swedish life science SME developing an injectable treatment (STA-363) for chronic low back pain (cLBP) caused by spinal disc degeneration.
ClBP is one of the costliest and most disabling conditions globally affecting the lives of over 50 million people in the EU and U.S., with the total costs for society in the U.S. alone $100 -200 billion. Over two thirds of patients with discogenic cLBP are not helped by the conservative treatment options of painkillers and physiotherapy, and only a small fraction are eligible for a spinal fusion surgery, the last line of treatment. The project focuses on gaining in-depth market understanding on the patient side as well taking a better look at potential partners.
Impact of the project:
The project brings hope to ClBP sufferers in their debilitating condition.
Funding instrument Horizon 2020 SME instrument phase 1
Spinverse’s role
Spinverse provided strong support in project planning, funding proposal writing and the evaluation of the quality of the proposal before submission.
Supporting the UN Sustainable Development Goals
We share what we learn
Read our latest news on our references
